Skip to main content
main-content

14-06-2021 | ASCO 2021 | Conference coverage | Video

Pembrolizumab benefit confirmed for cisplatin-ineligible advanced UC patients

Peter O’Donnell gives an update on the KEYNOTE-052 trial findings for first-line pembrolizumab in cisplatin-ineligible patients with advanced urothelial carcinoma (2:36).

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Read transcript

ESMO Congress 2021

Access our ongoing coverage including the latest news and expert video interviews.

Image Credits